VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating)'s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.13 and traded as low as $0.85. VBI Vaccines shares last traded at $0.87, with a volume of 810,237 shares changing hands.
Analyst Upgrades and Downgrades
Separately, Raymond James decreased their price target on VBI Vaccines from $6.00 to $5.00 and set a "strong-buy" rating on the stock in a report on Tuesday, August 9th.
Get VBI Vaccines alerts:VBI Vaccines Stock Down 1.6 %
The company has a 50-day simple moving average of $0.94 and a 200 day simple moving average of $1.13. The company has a market cap of $224.55 million, a P/E ratio of -2.23 and a beta of 1.86. The company has a current ratio of 2.29, a quick ratio of 2.19 and a debt-to-equity ratio of 0.20.
VBI Vaccines (NASDAQ:VBIV – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.11). The business had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.70 million. VBI Vaccines had a negative net margin of 15,391.36% and a negative return on equity of 75.37%. On average, equities analysts anticipate that VBI Vaccines Inc. will post -0.37 EPS for the current year.Hedge Funds Weigh In On VBI Vaccines
A number of hedge funds and other institutional investors have recently made changes to their positions in VBIV. State Street Corp grew its position in shares of VBI Vaccines by 31.1% during the 1st quarter. State Street Corp now owns 16,216,811 shares of the biopharmaceutical company's stock worth $26,920,000 after buying an additional 3,844,698 shares in the last quarter. Millennium Management LLC grew its position in shares of VBI Vaccines by 211.7% during the 2nd quarter. Millennium Management LLC now owns 1,780,752 shares of the biopharmaceutical company's stock worth $1,440,000 after buying an additional 1,209,393 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of VBI Vaccines by 358.7% during the 2nd quarter. Renaissance Technologies LLC now owns 789,500 shares of the biopharmaceutical company's stock worth $638,000 after buying an additional 617,400 shares in the last quarter. Frontier Wealth Management LLC grew its position in shares of VBI Vaccines by 1,571.7% during the 1st quarter. Frontier Wealth Management LLC now owns 601,800 shares of the biopharmaceutical company's stock worth $951,000 after buying an additional 565,800 shares in the last quarter. Finally, Bank of America Corp DE grew its position in shares of VBI Vaccines by 88.9% during the 1st quarter. Bank of America Corp DE now owns 809,425 shares of the biopharmaceutical company's stock worth $1,343,000 after buying an additional 380,839 shares in the last quarter. Institutional investors own 39.96% of the company's stock.
About VBI Vaccines
(Get Rating)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
Recommended Stories
- Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.